Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics ...
Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.
T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell ...
In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results